RaQualia Pharma Inc. provided consolidated earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expects net sales of JPY 2,605 million, operating profit of JPY 420 million, profit attributable to owners of parent of JPY 342 million and basic earnings per share of JPY 16.34.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
599 JPY | -0.83% | -1.64% | -12.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.94% | 82.93M | |
+30.29% | 699B | |
+25.07% | 571B | |
-4.45% | 364B | |
+18.21% | 326B | |
+3.70% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.39% | 154B |
- Stock Market
- Equities
- 4579 Stock
- News RaQualia Pharma Inc.
- RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022